Menstrual cycle-associated changes in blood levels of interleukin-6, α1 acid glycoprotein, and C-reactive protein

1997 ◽  
Vol 130 (1) ◽  
pp. 69-75 ◽  
Author(s):  
Bernd Jilma ◽  
EVA Dirnberger ◽  
Isabella Löscher ◽  
Anna Rumplmayr ◽  
Jörg Hildebrandt ◽  
...  
Keyword(s):  
Menstrual Cycle ◽  
Interleukin 6 ◽  
Blood Levels ◽  
C Reactive Protein ◽  
Acid Glycoprotein ◽  
Reactive Protein

scholarly journals Gulf War Illness-associated increases in blood levels of interleukin 6 and C-reactive protein: biomarker evidence of inflammation

2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Tammy A. Butterick ◽  
Janeen H. Trembley ◽  
Laura L. Hocum Stone ◽  
Clemma J. Muller ◽  
Rebecca R. Rudquist ◽  
...  
Keyword(s):  
Chronic Inflammation ◽  
Interleukin 6 ◽  
Well Being ◽  
Gulf War ◽  
Blood Levels ◽  
C Reactive Protein ◽  
Gulf War Illness ◽  
Memory Impairments ◽  
Reactive Protein ◽  
Gastrointestinal Problems

Abstract Objective Gulf War Illness is a chronic multisymptom disorder severely impacting the health and well-being of many Veterans of the 1990–1991 Gulf War. Symptoms that define the disease include pain, fatigue, mood and memory impairments, gastrointestinal problems, lung disorders, and skin rashes. In our previous biomarker study, we discovered Gulf War Illness-associated proinflammatory blood biomarkers. Therefore, we hypothesized that chronic inflammation causes the symptoms that define this disorder. Testing the chronic inflammation hypothesis is the objective of this study. Results The biomarker fingerprint of Gulf War Illness is the end-product of a cascade of proinflammatory cytokine signals. In particular, the observed increase in C-reactive protein predicts a corresponding increase in interleukin 6, the cytokine that stimulates hepatocytes to produce C-reactive protein. Therefore, in this study we measured potential upstream cytokine signals in plasma samples from Gulf War Veterans. As predicted, a positive correlation between interleukin 6 and C-reactive protein was observed.

scholarly journals In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets

Blood ◽  
1990 ◽  
Vol 75 (8) ◽  
pp. 1602-1605 ◽  
Author(s):  
S Asano ◽  
A Okano ◽  
K Ozawa ◽  
T Nakahata ◽  
T Ishibashi ◽  
...  
Keyword(s):  
Interleukin 6 ◽  
C Reactive Protein ◽  
Subcutaneous Injections ◽  
Acid Glycoprotein ◽  
Reactive Protein ◽  
Morphologic Analysis ◽  
In Vivo Effects ◽  
Dose Dependent ◽  
Second Peak

In cynomolgus monkeys, twice daily subcutaneous injections of recombinant human interleukin-6 (rhIL-6) at doses of 5 to 80 micrograms/kg/d for 14 consecutive days caused dose-dependent increases in platelet count, usually continuing for more than 1 week after cessation of the injections. The count reached a level approximately twofold or more above the preinjection level even at 5 micrograms/kg/d, and at doses of more than 20 micrograms/kg/d, the increase became biphasic with a higher second peak 3 days after cessation of the injections. Morphologic analysis of the bone marrow after the 7 day- injections with 80 micrograms/kg/d revealed a marked increment in size of megakaryocytes compared with control, indicating the promotion of megakaryocyte maturation. Other changes attributable to the rhIL-6 treatment include dose-dependent loss of body weight, anemia, neutrophilia and monocytosis, elevation of serum C-reactive protein and alpha-1 acid glycoprotein levels, and decrease of serum albumin; all of which returned to normal within 1 week after cessation of the injections and were tolerable at doses of less than 10 micrograms/kg/d. These findings suggest that rhIL-6 may be an effective strategy for the treatment of thrombocytopenia.

scholarly journals In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets

Blood ◽  
1990 ◽  
Vol 75 (8) ◽  
pp. 1602-1605 ◽  
Author(s):  
S Asano ◽  
A Okano ◽  
K Ozawa ◽  
T Nakahata ◽  
T Ishibashi ◽  
...  
Keyword(s):  
Interleukin 6 ◽  
C Reactive Protein ◽  
Subcutaneous Injections ◽  
Acid Glycoprotein ◽  
Reactive Protein ◽  
Morphologic Analysis ◽  
In Vivo Effects ◽  
Dose Dependent ◽  
Second Peak

Abstract In cynomolgus monkeys, twice daily subcutaneous injections of recombinant human interleukin-6 (rhIL-6) at doses of 5 to 80 micrograms/kg/d for 14 consecutive days caused dose-dependent increases in platelet count, usually continuing for more than 1 week after cessation of the injections. The count reached a level approximately twofold or more above the preinjection level even at 5 micrograms/kg/d, and at doses of more than 20 micrograms/kg/d, the increase became biphasic with a higher second peak 3 days after cessation of the injections. Morphologic analysis of the bone marrow after the 7 day- injections with 80 micrograms/kg/d revealed a marked increment in size of megakaryocytes compared with control, indicating the promotion of megakaryocyte maturation. Other changes attributable to the rhIL-6 treatment include dose-dependent loss of body weight, anemia, neutrophilia and monocytosis, elevation of serum C-reactive protein and alpha-1 acid glycoprotein levels, and decrease of serum albumin; all of which returned to normal within 1 week after cessation of the injections and were tolerable at doses of less than 10 micrograms/kg/d. These findings suggest that rhIL-6 may be an effective strategy for the treatment of thrombocytopenia.

Sign in / Sign up

Export Citation Format

Share Document